2021 年第 12 期 第 16 卷

扶正化瘀片联合复方鳖甲软肝片对肝硬化患者肝纤维化及炎症指标的改善作用

Effects of Fuzheng Huayu tablets and compound Biejia Ruangan tablets on liver fibrosis and inflammatory factors in patients with liver cirrhosis

作者：邱实1程静屏2

英文作者：Qiu Shi1 Cheng Jingping2

单位：1华润武钢总医院消化内科，武汉430080；2华润武钢总医院老年病科，武汉430080

英文单位：1Department of Gastroenterology China Resources WISCO General Hospital Wuhan 430080 China; 2Department of Geriatrics China Resources WISCO General Hospital Wuhan 430080 China

关键词：肝硬化；扶正化瘀片；复方鳖甲软肝片；肝纤维化；炎症因子

英文关键词：Livercirrhosis;FuzhengHuayutablets;CompoundBiejiaRuangantablets;Liverfibrosis;Inflammatoryfactors

• 摘要：

• 目的 探讨在抗病毒治疗基础上，扶正化瘀片联合复方鳖甲软肝片对乙型肝炎肝硬化患者肝纤维化及炎症指标的改善作用。方法 选取华润武钢总医院2019年12月至2020年12月收治的90例乙型肝炎肝硬化患者，采用随机数字表法分为对照组和观察组，各45例。对照组患者口服恩替卡韦片治疗；观察组患者在对照组基础上口服复方鳖甲软肝片和扶正化瘀片治疗。治疗3个月，比较2组患者肝功能指标、肝纤维化指标、炎症因子水平和生存质量。结果  治疗后，2组患者丙氨酸转氨酶、天冬氨酸转氨酶、白蛋白、层黏连蛋白、血清透明质酸、Ⅳ型胶原蛋白水平和白细胞介素6、肿瘤坏死因子α、内皮素1水平均低于治疗前，且观察组以上指标均低于对照组（均P＜0.05）。治疗后，2组患者生存质量各项评分均高于治疗前，且观察组生存质量总评分高于对照组［（76.3±9.8）分比（67.7±10.1）分］（均P＜0.05）。结论  对乙型肝炎肝硬化患者，在抗病毒治疗的基础上，使用扶正化瘀片联合复方鳖甲软肝片进行治疗，不仅可改善患者的肝功能及肝纤维化，同时可降低血清炎症因子水平，提高患者的整体生存质量。

• Objective To explore the effect of Fuzheng Huayu tablets combined with compound Biejia Ruangan tablets on liver fibrosis and inflammatory factors on the basis of antiviral therapy in patients with liver cirrhosis caused by hepatitis B virus. Methods From December 2019 to December 2020, 90 patients with hepatitis B cirrhosis treated in China Resources WISCO General Hospital were enrolled. They were randomly divided into control group and observation group, with 45 cases in each group. Patients in control group were treated with entecavir tablets and patients in observation group were treated with compound Biejia Ruangan tablets and Fuzheng Huayu tablets on the basis of the control group. The liver function indexes, liver fibrosis indexes, inflammatory factors levels and quality of life were compared between the two groups 3 months after treatment. Results After treatment, the levels of alanine aminotransferase, aspartate aminotransferase, albumin, laminin, serum hyaluronic acid, type Ⅳ collagen, interleukin-6, tumor necrosis factor-α and endothelin-1 in the two groups were lower than those before treatment, and those in observation group were lower than those in control group (all P＜0.05). After treatment, the scores of quality of life in the two groups were higher than those before treatment, and the total score of quality of life in observation group was higher than that in control group［（76.3±9.8） vs （67.7±10.1）］(all P＜0.05). Conclusion  On the basis of antiviral therapy, Fuzheng Huayu tablets combined with compound Biejia Ruangan tablets can improve the liver function and liver fibrosis of the patients with liver cirrhosis, reduce the inflammation factors, and improve the overall quality of life.